Omnicell (NASDAQ:OMCL) posted its quarterly earnings results on Tuesday. The company reported $0.37 EPS for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.14, MarketWatch Earnings reports. The business had revenue of $199.62 million during the quarter, compared to the consensus estimate of $182.16 million. Omnicell had a return on equity of 9.21% and a net margin of 5.42%. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period last year, the firm earned $0.67 earnings per share. Omnicell updated its Q3 2020
After-Hours guidance to 0.44-0.52 EPS and its Q3 guidance to $0.44-0.52 EPS.

Shares of OMCL traded down $1.79 during mid-day trading on Friday, reaching $69.54. 9,240 shares of the company’s stock traded hands, compared to its average volume of 288,522. The business’s 50-day moving average price is $67.15 and its 200-day moving average price is $72.74. The stock has a market capitalization of $2.98 billion, a P/E ratio of 63.12, a price-to-earnings-growth ratio of 2.88 and a beta of 1.03. Omnicell has a 12 month low of $54.24 and a 12 month high of $94.85.

In other Omnicell news, EVP Scott Peter Seidelmann sold 2,125 shares of Omnicell stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $67.70, for a total transaction of $143,862.50. Following the transaction, the executive vice president now directly owns 33,385 shares in the company, valued at approximately $2,260,164.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Randall A. Lipps sold 3,718 shares of Omnicell stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $75.15, for a total transaction of $279,407.70. Following the transaction, the chief executive officer now owns 152,116 shares in the company, valued at $11,431,517.40. The disclosure for this sale can be found here. Insiders own 2.63% of the company’s stock.

A number of equities analysts recently commented on the company. ValuEngine downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Friday, April 17th. Piper Sandler decreased their price target on Omnicell from $76.00 to $70.00 and set a “neutral” rating for the company in a research note on Wednesday. BidaskClub downgraded Omnicell from a “hold” rating to a “sell” rating in a research note on Wednesday, July 8th. Benchmark decreased their price target on Omnicell from $96.00 to $82.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Cantor Fitzgerald lifted their target price on Omnicell from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $85.50.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Featured Article: Stock Portfolio Tracker

Earnings History for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.